Barinthus Biotherapeutics (BRNS) Invested Capital (2020 - 2025)
Historic Invested Capital for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $84.6 million.
- Barinthus Biotherapeutics' Invested Capital fell 4697.07% to $84.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.6 million, marking a year-over-year decrease of 4697.07%. This contributed to the annual value of $130.1 million for FY2024, which is 3040.72% down from last year.
- Latest data reveals that Barinthus Biotherapeutics reported Invested Capital of $84.6 million as of Q3 2025, which was down 4697.07% from $102.5 million recorded in Q2 2025.
- In the past 5 years, Barinthus Biotherapeutics' Invested Capital ranged from a high of $254.8 million in Q2 2022 and a low of -$52.8 million during Q1 2021
- For the 5-year period, Barinthus Biotherapeutics' Invested Capital averaged around $181.2 million, with its median value being $195.6 million (2023).
- Per our database at Business Quant, Barinthus Biotherapeutics' Invested Capital skyrocketed by 78465.81% in 2021 and then crashed by 4697.07% in 2025.
- Barinthus Biotherapeutics' Invested Capital (Quarter) stood at $252.7 million in 2021, then dropped by 3.77% to $243.2 million in 2022, then dropped by 23.11% to $187.0 million in 2023, then tumbled by 30.41% to $130.1 million in 2024, then tumbled by 35.02% to $84.6 million in 2025.
- Its Invested Capital stands at $84.6 million for Q3 2025, versus $102.5 million for Q2 2025 and $115.6 million for Q1 2025.